Zhidong Wang - Publications
Affiliations: | 2018-2022 | Peking University, Beijing, Beijing Shi, China |
Year | Citation | Score | |||
---|---|---|---|---|---|
2022 | Liu D, Qi X, Wei X, Zhao L, Wang X, Li S, Wang Z, Shi L, Xu J, Hong M, Liu Z, Zhao L, Wang X, Zhang B, Zhang Y, et al. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy. Theranostics. 12: 7788-7803. PMID 36451856 DOI: 10.7150/thno.75037 | 0.536 | |||
2022 | Guo H, Wang M, Wang B, Guo L, Cheng Y, Wang Z, Sun YQ, Wang Y, Chang YJ, Huang XJ. PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome. Frontiers in Immunology. 13: 879501. PMID 35572579 DOI: 10.3389/fimmu.2022.879501 | 0.34 | |||
2021 | Cao YJ, Wang X, Wang Z, Zhao L, Li S, Zhang Z, Wei X, Yun H, Choi SH, Liu Z, Zhao L, Kazane SA. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. Acs Synthetic Biology. PMID 33856201 DOI: 10.1021/acssynbio.1c00007 | 0.546 | |||
2020 | Wang Z, Cao YJ. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. Frontiers in Immunology. 11: 176. PMID 32194541 DOI: 10.3389/Fimmu.2020.00176 | 0.5 | |||
Show low-probability matches. |